Anti-inflammatory and immune regulatory properties of 5-androsten-3β, 17β-diol (HE2100), and synthetic analogue HE3204: Implications for treatment of autoimmune diseases

Annals of the New York Academy of Sciences

Volumn 1051, Issue , 2005, Pages 730-742

  Auci, Dominic ^a,e   Nicoletti, F ^b   Mangano, K ^b   Pieters, R ^c   Nierkens, S ^c   Morgan, L ^a   Offner, H ^d   Frincke, J ^a   Reading, C ^a  

^a HollisEden Pharmaceuticals   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

^c UTRECHT UNIVERSITY   (Netherlands)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e 4435 Eastgate Mall ^*  (United States)

Author keywords

Autoimmune disease; DHEA; Immune regulating hormones; Steroids

Indexed keywords

16ALPHA BROMOEPIANDROSTERONE; 5 ANDROSTENE 17BETA AMINO 3 OL; ANDROSTENEDIOL; CARRAGEENAN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FLUASTERONE; GAMMA INTERFERON; HE 2100; HE 3204; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; INTERLEUKIN 4; OVALBUMIN; PICRIC ACID; PRASTERONE; STEROID; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BIOAVAILABILITY; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HELPER CELL; HORMONAL REGULATION; IMMUNOREGULATION; MALE; MOUSE; NONHUMAN; T LYMPHOCYTE ACTIVATION;

MURINAE;

EID: 25444502312     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1361.117     Document Type: Conference Paper

References (19)

1. BLAUER, K.L., M. POTH, W.M. ROGERS & E.W. BERNTON. 1991. Dehydroepiandrosterone antagonizes the suppressive effects of dexamethasone on lymphocyte proliferation. Endocrinology 129: 3174-3179.
2. DAYNES, R.A., D.J. DUDLEY & B.A. ARANEO. 1990. Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur. J. Immunol. 20: 793-802.
3. SUZUKI, T., N. SUZUKI, R.A. DAYNES & E.G. ENGLEMAN. 1991. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin. Immunol. Immunopathol. 61: 202-211.
4. DAYNES, R.A. & B.A. ARANEO. 1994. The development of effective vaccine adjuvants employing natural regulators of T-cell lymphokine production in vivo. Ann. NY Acad. Sci. 730: 144-161.
5. LORIA, R.M., D.A. PADGETT & P.N. HUYNH. 1996. Regulation of the immune response by dehydroepiandrosterone and its metabolites. J. Endocrinol. 150 (Suppl): S209-S220.
6. PADGETT, D.A., R.M. LORIA & J.F. SHERIDAN. 1997. Endocrine regulation of the immune response to influenza virus infection with a metabolite of DHEA-androstenediol. J. Neuroimmunol. 78: 203-211.
7. BEN-NATHAN, D., D.A. PADGETT & R.M. LORIA. 1999. Androstenediol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysaccharide toxicity. J. Med. Microbiol. 48: 25-31.
8. CANNING, M.O., K. GROTENHUIS, H.J. DE WIT & H.A. DREXHAGE. 2000. Opposing effects of dehydroepiandrosterone and dexamethasone on the generation of monocyte-derived dendritic cells. Eur. J. Endocrinol. 143: 687-695.
9. CLERICI, M., D. TRABATTONI, S. PICONI, et al. 1997. A possible role for the cortisol/anticortisols imbalance in the progression of human immunodeficiency virus. Psychoneuroendocrinology 22: S27-S31.
10. SPENCER, N.F., S.D. NORTON, L.L. HARRISON, et al. 1996. Dysregulation of IL-10 production with aging: possible linkage to the age-associated decline in DHEA and its sulfated derivative. Exp. Gerontol. 31: 393-408.
11. DAYNES, R.A. & B.A. ARANEO. 1992. Prevention and reversal of some age-associated changes in immunologic responses by supplemental dehydroepiandrosterone sulfate therapy. Aging: Immunol. Infect. Dis. 3: 135-153.
12. DIAMOND, P., L. CUSAN, J.L. GOMEZ, et al. 1996. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J. Endocrinol. 150 (Suppl): S43-S50.
13. MARWAH, A., P. MARWAH & H. LARDY. 2002. Ergosteroids. VI. Metabolism of dehydroepiandrosterone by rat liver in vitro: a liquid chromatographic-mass spectrometric study. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 767: 285-299.
14. PIETERS, R. & R. ALBERS. 1999. Assessment of autoimmunogenic potential of xenobiotics using the popliteal lymph node assay. Methods 19: 71-77.
15. SCHIELEN, P., W. VAN RODIJNEN, J. TEKSTRA, et al. 1995. Quantification of natural antibody producing B cells in rats by an improved ELISPOT technique using the polyvinylidene difluoride membrane as the solid support. J. Immunol. Methods 188: 33-41.
16. BEBO, B.F., JR., A. FYFE-JOHNSON, K. ADLARD, et al. 2001. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J. Immunol. 166: 2080-2089.
17. VOSKUHL, R.R. & K. PALASZYNSKI. 2001. Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neuroscientist 7: 258-270.
18. DU, C., M.W. KHALIL & S. SRIRAM. 2001. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J. Immunol. 167: 7094-7101.
19. OFFNER, H., A. ZAMORA, H. DROUGHT, et al. 2002. A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE. J. Neuroimmunol. 130: 128.